Start Date
October 1, 2021
Primary Completion Date
December 16, 2022
Study Completion Date
December 16, 2022
Infigratinib
Hard gelatin capsules for oral use
Memorial Sloan Kettering Cancer Center, New York
Nicklaus Children's Hospital, Miami
Universitaetsklinikum Heidelberg (UKHD) - Zentrum fuer Kinder- und Jugendmedizin - Klinik Kinderheilkunde III, Heidelberg
Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto
Children's National Hospital - Brain Tumor Institute, Washington D.C.
Duke Cancer Institute (DCI) - The Preston Robert Tisch Brain Tumor Center, Durham
UPCM - Children's Hospital of Pittsburgh, Pittsburgh
University of Alberta - Stollery Children's Hospital (SCH), Edmonton
McMaster Children's Hospital (MCH), Hamilton
University of Toronto - The Hospital for Sick Children (SickKids), Toronto
Lead Sponsor
Labcorp Corporation of America Holdings, Inc
INDUSTRY
Helsinn Healthcare SA
INDUSTRY